Which pharmaceutical is suggested for a woman at high risk of breast cancer with elevated lipids?

• A. Tamoxifen
• B. Evista (Raloxifene)
• C. Alendronate
• D. Calcitonin

Answer: (B)

The suggested pharmaceutical for a woman at high risk of breast cancer with elevated lipids is Raloxifene, commonly known by the brand name Evista. Raloxifene is a selective estrogen receptor modulator (SERM) that is effective in reducing the risk of invasive breast cancer in postmenopausal women. Furthermore, Raloxifene has a positive impact on lipid profiles by lowering LDL (low-density lipoprotein) cholesterol levels, which is beneficial for patients with elevated lipids.

In contrast, while Tamoxifen is another SERM used for breast cancer prevention and treatment, it may not be as favorable for women with elevated lipids as Raloxifene, given the latter's added benefit on lipid management. Alendronate is primarily used for osteoporosis treatment and does not have a role in breast cancer risk reduction. Calcitonin is mainly used for conditions like osteoporosis but does not provide benefits related to breast cancer risk. Thus, Raloxifene stands out as the best option for the specific scenario presented.